M&A Deal Summary

Boston Scientific Acquires Obsidio

On August 15, 2022, Boston Scientific acquired medical products company Obsidio

Acquisition Highlights
  • This is Boston Scientific’s 45th transaction in the Medical Products sector.
  • This is Boston Scientific’s 45th transaction in the United States.
  • This is Boston Scientific’s 1st transaction in South Carolina.

M&A Deal Summary
Date 2022-08-15
Target Obsidio
Sector Medical Products
Buyer(s) Boston Scientific
Deal Type Add-on Acquisition

Target

Obsidio

Columbia, South Carolina, United States
Obsidio is a privately-held company that has developed the Gel Embolic Material technology used for embolization of blood vessels in the peripheral vasculature. Obsidio is based in Columbia, South Carolina.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boston Scientific

Marlborough, Massachusetts, United States
Category Company
Founded 1979
Sector Medical Products
Employees48,000
Revenue 14.2B USD (2023)
DESCRIPTION
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.

Boston Scientific is a medical technology company. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 59 of 66
Sector (Medical Products) 45 of 50
Type (Add-on Acquisition) 46 of 51
State (South Carolina) 1 of 1
Country (United States) 45 of 51
Year (2022) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-15 M.I.Tech

Pyeongtaek-si, South Korea

M.I.Tech develops, manufactures, and provides its own unique medical devices in the field of digestive endoscopy to improve patients’ quality of life. It manufactures all products under a strict quality management system by maintaining the global standard, ISO 13485:2003. M.I.Tech was formed in 1991 and is based in Pyeongtaek-si, South Korea.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-29 Apollo Endosurgery

Austin, Texas, United States

Apollo Endosurgery is a developer of therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company concluded mid-stage clinical development of drug candidates iSONEP™ (sphingomab) in wet age-related macular degeneration and ASONEP™ (anti-S1P antibody for systemic delivery) in renal cell carcinoma in 2015. Apollo Endosurgery was incorporated in 2005 and is based in Austin, Texas.

Buy $615M
Mergr

Product

Company

Legal